Loading...
Dec 14, 2022 - Jun 13, 2023

Jenburkt Pharmaceuticals Ltd Buyback (Jenburkt-Pharmaceuticals-Buyback) Detail

Jenburkt Pharmaceuticals Ltd manufactures and markets pharmaceutical formulations in India and internationally across 13 countries. The company has over 850+ committed team members across functions pan-India, the company promote all the 85 brands across 100,000+ doctors regularly.

The company has more than 1,000 stockists and the company's reach extends to 400,000+ pharmacies across the globe. The company's products are also being exported to 13 countries globally.

The company has Research & Development unit, duly approved by the Ministry of Science & Technology, Government of India, has been set up to develop finished formulations in the therapeutic areas of Geriatrics, Diabetology, Pain management and Neutraceuticals.

Jenburkt-Pharmaceuticals-Buyback Detail

Issue PeriodDec 14, 2022 - Jun 13, 2023
Security NameJenburkt Pharmaceuticals Ltd
Issue TypeOpen Market Through Stock Exchange
Issue Size (Amount)₹11.60 Crores
Buyback Price₹702 per share
Face Value₹10 per share
Listing AtBSE

Company Financials

Jenburkt Pharmaceuticals Ltd Financial Information (Restated)
Period EndedTotal RevenueProfit After TaxNet WorthTotal Borrowing
31-Mar-20123.1114.8782.345.18
31-Mar-21113.616.598.855.07
31-Mar-22128.9322.3116.466.76
Amount in ₹ Crore

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2022 645.15 572 590.12
Oct-2022 577.25 548.65 563.91
Sep-2022 605.95 535.7 581.48

Necessity of the Issue

The buyback is being undertaken for the following reason:

  • The company is expected to achieve the objective of returning surplus funds to the shareholders, improving return on equity through distribution of surplus funds, improving earnings per share by reduction in equity base and increasing shareholders' value in the long term by improving key return ratios.
  • The Buyback will lead to reduction in outstanding Equity Shares of the Company, improvement in 'earnings per share' and enhanced return on equity.

Jenburkt-Pharmaceuticals-Buyback Documents

Jenburkt-Pharmaceuticals-Buyback Rating

0
0.0
Rating:Rated 0.0 stars
Vote Here ...

Jenburkt-Pharmaceuticals-Buyback Reviews

Sorry, we couldn't find any reviews, please check back later.

Company Contact Information

Jenburkt Pharmaceuticals Ltd
Nirmala Apartments, 93,
J. P. Road, Andheri (W),
Mumbai 400058,

Phone: +91 22 67603603
Email: info@jenburkt.com
Website: https://jenburkt.com/

Jenburkt-Pharmaceuticals-Buyback Registrar

  1. Bigshare Services Pvt Ltd
       1st Floor, Bharat Tin Works Building,
       Opp. Vasant Oasis,Makwana Road,
       Marol, Andheri(E), Mumbai - 400 059

    Phone: +91-22-6263 8200
    Email: buybackoffer@bigshareonline.com
    Website: http://www.bigshareonline.com

Jenburkt-Pharmaceuticals-Buyback Manager

Lead Manager(s)

  1. DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd)

Registered Broker

  1. DAM Capital Advisors Limited
    Email: rajesh@damcapital.in

Find Jenburkt-Pharmaceuticals-Buyback Latest Update

Jenburkt-Pharmaceuticals-Buyback FAQs

The Jenburkt-Pharmaceuticals-Buyback opens on Dec 14, 2022, and closes on Jun 13, 2023.

The Jenburkt-Pharmaceuticals-Buyback is a Open Market Through Stock Exchange.

Jenburkt-Pharmaceuticals-Buyback Schedule

Buyback Opening DateDec 14, 2022
Buyback Closing DateJun 13, 2023
Last date for acceptance of sharesUpon relevant pay-out by the Stock exchange

The Jenburkt-Pharmaceuticals-Buyback is being offered at Rs ₹702 per share per equity share.

There is no ratio applicable in case of open market offer through stock exchange mechanism.

There is no concept of record date in case of open market through stock exchange mechanism.

The Jenburkt-Pharmaceuticals-Buyback has announced a buyback for an aggregate amount of not more than Rs. ₹11.60 Crores with pricing of Rs.₹702 per share.

The buyback is being undertaken for the following reason:

  • The company is expected to achieve the objective of returning surplus funds to the shareholders, improving return on equity through distribution of surplus funds, improving earnings per share by reduction in equity base and increasing shareholders' value in the long term by improving key return ratios.
  • The Buyback will lead to reduction in outstanding Equity Shares of the Company, improvement in 'earnings per share' and enhanced return on equity.

Any equity shareholder holding the shares in Demat form can participate in the buyback offer through their stockbroker. The physical shareholder can participate only once the shares get converted into a Dematerialized form.

The shareholder needs to inform their broker on the details of the Equity shares they wish to sell. The broker will place a sell order whenever the company places a buy order for the buyback. The trade would get executed at the offer price or lesser only when the price offered by the shareholder matches with the buy order placed by the company.

The Jenburkt-Pharmaceuticals-Buyback offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.


Comments

Add a public comment...